摘要
目的研究对溃疡性结肠炎患者实施胶体酒石酸铋胶囊结合美沙拉嗪治疗的效果。方法该研究于2020年1月正式开始,截止时间为2022年12月,将此时间段内南华大学附属长沙中心医院收治的112例溃疡性结肠炎患者作为研究对象,并采用数字随机分组方式将患者分为A组、B组,对A组患者实施美沙拉嗪治疗,B组在此基础上再使用胶体酒石酸铋胶囊治疗,对比两组患者治疗前后炎症因子水平、氧化应激反应指标、生活质量水平以及两组患者的临床疗效。结果治疗前,A组、B组患者的相关指标相似度较高(P>0.05)。治疗后,B组各指标均优于A组,且B组治疗有效率明显高于A组,组间数据差异较大(P<0.05)。结论针对存在溃疡性结肠炎症状的患者,治疗过程中使用胶体酒石酸铋剂结合美沙拉嗪的疗效较好,值得临床推荐使用。
Objective To study the effect of colloidal bismuth tartrate capsule plus mesalazine on patients with ulcerative colitis.Methods This study officially started in January 2020 and ended in December 2022.112 patients with ulcerative colitis admitted to our hospital during this period were taken as research objects,and the patients were divided into two groups by digital randomization.Patients in group A were treated with mesalazine,and patients in group B were treated with colloidal bismuth tartrate capsules on this basis.The levels of inflammatory factors,oxidative stress indexes,quality of life and clinical efficacy of the two groups were compared before and after treatment.Results Before treatment,the correlation indexes of group A and group B were similar(P>0.05).After treatment,all indexes of group B were better than those of group A,and the treatment effective rate of group B was significantly higher than that of group A,and the data difference between groups was large(P<0.05).Conclusion For patients with ulcerative colitis symptoms,the use of colloidal bismuth tartrate combined with mesalazine in the course of treatment is effective,worthy of clinical recommendation.
作者
李清福
Li Qingfu(Changsha Central Hospital Affiliated to Nanhua University,Changsha,Hunan 410004,China)
出处
《首都食品与医药》
2023年第24期42-44,共3页
Capital Food Medicine
关键词
溃疡性结肠炎
药物治疗
炎症因子
ulcerative colitis
Medication
Inflammatory factor
